ArticleHormones (Athens, Greece)2025
Identification of the serum uric acid threshold with increasing risk for diabetic nephropathy in type 1 diabetes.
Article in Hormones (Athens, Greece), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Higher serum uric acid levels are associated with improved outcomes in acute ischemic stroke patients following intravenous thrombolysis with alteplase-a retrospective cohort study.Frontiers in neurology · 2026Article
- Parathyroid disease, gut microbiome, biologic age, and more.Hormones (Athens, Greece) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeTo investigate the correlation between serum uric acid (SUA) levels and the risk for diabetic nephropathy (DN) in Chinese patients with type 1 diabetes mellitus (T1DM) and determine the potential optimal SUA threshold.
methodsIn this case-control study, 913 T1DM patients were matched 1:1 with healthy controls by age and sex. Multivariable adjusted logistic regression analysis was used to investigate the association between SUA levels and the risk of developing DN. Restricted cubic spline (RCS) was applied to investigate the optimal threshold for SUA. Additionally, longitudinal analysis of 94 patients with at least three visits accessed SUA variability correlations with estimated glomerular filtration rate (eGFR) and urinary albumin creatinine ratio (UACR) changes using Spearman's correlation analysis. A linear mixed-effects model was performed to access the correlations in SUA, eGFR, and UACR over time.
resultsT1DM patients exhibited significantly lower median SUA levels (4.24 vs. 4.93 mg/dL, P < 0.001) than controls. The incidence of DN was 12% in T1DM patients. After adjusting for confounding factors, the SUA level was inversely significantly correlated with the risk for DN as a continuous variable (OR: 1.47; 1.25-1.74) and in quartile 4 (OR: 3.01; 1.44-6.50), respectively. The RCS plot revealed an identified threshold of SUA as being 4.30 mg/dL with increasing risk for DN. Correlation analysis showed the SUA variability significantly correlate with eGFR variability (r = 0.206, P = 0.046) and UACR variability (r = 0.405, P = 0.025). The linear mixed-effects model revealed a significant negative relationship between SUA and eGFR over time (R
conclusionsOur study revealed that decreased SUA level is common in T1DM and identified the threshold as being 4.30 mg/dL for increased DN risk.
Indexed as
Identifiers
40627329What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.